Experimental Injection Shows Promise in Reducing Dangerous Abdominal Fat
A novel injectable drug, CBL-514, has demonstrated potential to reduce both subcutaneous and visceral fat by triggering fat cell self-destruction, according to early phase 2 clinical trials. This emerging research may open new avenues for obesity treatment and weight maintenance.
What stood out to you, and what would you like the community to explore further?
Community discussion is general information only and is not medical advice, a diagnosis, prescribing guidance, or a promise of results.